【24h】

On prilled Nanotubes-in-Microgel Oral Systems for protein delivery

机译:在微囊化纳米管口服凝胶中输送蛋白质

获取原文
获取原文并翻译 | 示例
           

摘要

Newly discovered active macromolecules are highly promising for therapy, but poor bioavailability hinders their oral use. Microencapsulation approaches, such as protein prilling into microspheres, may enable protection from gastrointestinal (GI) enzymatic degradation. This would increase bioavailability mainly for local delivery to GI lumen or mucosa. This work's purpose was to design a novel architecture, namely a Nanotubes-in-Microgel Oral System, by prilling for protein delivery. Halloysite nanotubes (HNT) were selected as orally acceptable clay particles and their lumen was enlarged by alkaline etching. This chemical modification increased the luminal volume to a mean of 216.3 mu L g(-1) (+40.8%). After loading albumin as model drug, the HNT were entrapped in microgels by prilling. The formation of Nanoparticles-in-Microsphere Oral System (NiMOS) yielded entrapment efficiencies up to 63.2%. NiMOS shape was spherical to toroidal, with a diameter smaller than 320 mu m. Release profiles depended largely on the employed system and HNT type. Protein stability was determined throughout prilling and after in vitro enzymatic degradation. Prilling did not harm protein structure, and NiMOS demonstrated higher enzymatic protection than pure nanotubes or microgels, since up to 82% of BSA remained unscathed after in vitro digestion. Therefore, prilled NiMOS was shown to be a promising and flexible multi-compartment system for oral (local) macromolecular delivery. (C) 2016 Elsevier B.V. All rights reserved.
机译:新发现的活性大分子具有很高的治疗前景,但生物利用度差阻碍了它们的口服使用。微囊化方法,例如将蛋白质造粒到微球中,可以保护胃肠道(GI)免受酶降解。这将增加生物利用度,主要用于局部递送至胃肠腔或粘膜。这项工作的目的是设计一种新颖的体系结构,即通过微丸蛋白递送来设计纳米管-微凝胶口服系统。选择埃洛石纳米管(HNT)作为口腔可接受的粘土颗粒,并通过碱蚀扩大其内腔。这种化学修饰将腔体积增加到平均216.3μL g(-1)(+ 40.8%)。装载白蛋白作为模型药物后,通过造粒将HNT截留在微凝胶中。纳米微粒微球口服系统(NiMOS)的形成产生了高达63.2%的包封率。 NiMOS的形状为球形到环形,直径小于320微米。发行档案很大程度上取决于所使用的系统和HNT类型。在整个造粒过程中以及体外酶促降解后确定蛋白质的稳定性。造粒不会损害蛋白质结构,并且NiMOS表现出比纯纳米管或微凝胶更高的酶保护作用,因为在体外消化后,高达82%的BSA仍保持不变。因此,小颗粒NiMOS被证明是用于口服(局部)大分子递送的有前途且灵活的多室系统。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号